Document text
Final - February 26, 2024
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
Dr. Matt Daley (ACIP, WG Chair)
Dr. Christopher Taylor (CDC/NCIRD)
Dr. Kevin Chatham-Stephens (CDC/NCIRD)
Dr. Ruth Link-Gelles (CDC/NCIRD)Dr. Lisa Prosser (University of Michigan)Dr. Megan Wallace (CDC/NCIRD)Dr. Lakshmi Panagiotakopoulos (CDC/NCIRD)8:30 COVID-19 Vaccines
Introduction
COVID-19-associated hospitalizations among adults - COVID-NET
COVID-19 vaccination coverage updateCOVID-19 vaccine effectiveness Economic analysis of an additional dose of COVID-19 vaccineEvidence to Recommendations Next steps for the COVID-19 vaccine program
10:50 Break
11:10 Chikungunya VaccinesIntroductionUpdate on chikungunya vaccine licensure Review of proposed policy options for chikungunya vaccine use
among U.S. adults traveling abroad
Review of proposed policy options for chikungunya vaccine use
among laboratory workers
Vaccine use among pregnant and breastfeeding women Dr. Wilbur Chen (ACIP, WG Chair)
Dr. Susan Hills (CDC/NCEZID)Dr. Susan Hills (CDC/NCEZID)
Dr. Susan Hills (CDC/NCEZID)Dr. Susan Hills (CDC/NCEZID), Dr. Dana Meaney-Delman
(CDC/NCBDDD)
12:25 Break
1:25 DT Vaccine
Guidance to use Td vaccine for those instances when receipt of the
pertussis component is contraindicatedDr. Michelle Hughes (CDC/NCIRD)
Dr. Jeanne Santoli (CDC/NCIRD)
1:35 Break
1:40 Public Comment
2:00 VOTES COVID-19 Vaccines Chikungunya VaccineVFC VOTESDiphtheria, Tetanus, and Pertussis
Dr. Megan Wallace (CDC/NCIRD)Dr. Susan Hills (CDC/NCEZID)
Dr. Jeanne Santoli (CDC/NCIRD)
2:30 Break
2:40 Influenza Vaccines
Introduction
Interim Estimates of 2023–24 Seasonal Influenza Vaccine
Effectiveness
Interim Influenza Vaccine Effectiveness Against Laboratory-
Confirmed Influenza in California, October 2023—January 2024
Safety of LAIV4 in Children with Asthma
Influenza B/Yamagata Update Dr. Jamie Loehr (ACIP, WG Chair)
Dr. Aaron Frutos (CDC/NCIRD/ID)
Dr. Sophie Zhu (California Department of Public Health
and CDC/PHIC/DWD)
Dr. C. Buddy Creech (Vanderbilt University Medical
Center)
Dr. Lisa Grohskopf (CDC/NCIRD/ID)
4:10 Break
4:20 Polio Vaccines
Work Group deliberations on potential use of nOPV2 as an outbreak
control measure in the US
Clinical considerations for children who received fractional dose
inactivated polio vaccine (fIPV) in other countriesDr. Sarah Kidd (CDC/NCIRD)
Dr. Sarah Kidd (CDC/NCIRD)
CMS, FDA, HRSA, IHS, OIDP, NIH 5:10 Agency Updates
5:30 AdjournMEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
Centers for Disease Control and Prevention
Atlanta, Georgia 30329
February 28-29, 2024
Wednesday, February 28, 2024
8:00 Welcome & Introductions
Final - February 26, 2024
8:00 Welcome & Introductions Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:10 Respiratory syncytial virus (RSV) Vaccines Adults
IntroductionManufacturer presentation: Moderna safety & efficacy in adults aged
≥60 years
Risk-stratified rates of RSV-associated hospitalization among adults
Implementation update: older adult RSV vaccination
Post-marketing safety surveillance of older adult RSV vaccination
Preliminary Analysis of Guillain-Barré Syndrome (GBS) following RSV
Vaccination among adults 65 years and older
Older adult RSV vaccination: benefits and risks discussion
Work group interpretations and discussionDr. Camille Kotton (ACIP, WG Chair)
Dr Rituparna Das (Moderna)
Dr. Rebecca Woodruff (CDC/NCCDPHP)
Dr. Carla Black (CDC/NCIRD)
Dr. Tom Shimabukuro (CDC/NCIRD)
Dr. Patricia Lloyd (FDA)
Dr. Michael Melgar (CDC/NCIRD)
Dr. Amadea Britton (CDC/NCIRD)
11:10 Break
11:20 Meningococcal Vaccines Introduction Revising the Adolescent Meningococcal Vaccine Schedule: Term of
Reference and Considerations
GSK Pentavalent MenABCWY vaccine: Term of ReferenceDr. Jamie Loehr (ACIP, WG Chair)
Dr. Sarah Schillie (CDC/NCIRD)
Dr. Sarah Schillie (CDC/NCIRD)
12:00 Break
12:45 Pneumococcal Vaccines
IntroductionCurrent epidemiology of invasive pneumococcal disease and
pneumococcal vaccine coverage in adults
Preliminary findings of the Pneumococcal pNeumonia Epidemiology,
Urine serotyping, and Mental Outcomes (PNEUMO) US study
Phase 3 clinical trial data of PCV21
Post-licensure PCV20 safety data
PCV21 Policy Questions and Preliminary WG interpretations of EtRDr. Jamie Loehr (ACIP, WG Chair)
Mr. Ryan Gierke (CDC/NCIRD)
Dr. Wesley Self (Vanderbilt University Medical Center)
Dr. Heather Platt (Merck)
Dr. Pedro Moro (CDC/NCEZID), Dr. Richard Forshee (FDA)
Dr. Miwako Kobayashi (CDC/NCIRD)
3:00 Break
3:10 Combined Diphtheria and Tetanus Toxoids and Acellular Pertussis,
Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate,
and Hepatitis B vaccine (Vaxelis®)
Introduction
Background on invasive Hib disease and vaccination among American
Indian and Alaska Native Populations
The HibVax Study: Immunogenicity of H. influenzae type b PRP-OMP
vaccines in American Indian and Alaska Native infants
Work group considerationsDr. Jamie Loehr (ACIP, WG Chair)
Dr. Jennifer Collins (CDC/NCIRD)
Dr. Laura Hammitt (Johns Hopkins Bloomberg School of
Public Health - Center for Indigenous Health)
Dr. Jennifer Collins (CDC/NCIRD)
4:30 AdjournThursday, February 29, 2024
Final - February 26, 2024
Acronyms
CDC Centers for Disease Control and Prevention
CMS Centers for Medicare and Medicaid Services
COVID-19 Coronavirus disease 2019
EtR Evidence to Recommendations Framework
FDA Food and Drug Administration
GRADE Grading of Recommendations Assessment, Development and Evaluation
HRSA Health Resources and Services Administration
IHS Indian Health Service
NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention
NCIRD National Center for Immunization & Respiratory Diseases
NCEZID National Center for Emerging and Zoonotic Diseases
NIAID National Institute of Allergy and Infectious Diseases
OIDP Office of Infectious Disease and HIV/AIDS Policy
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2
WG Work Group
WHO World Health Organization
VE Vaccine Effectiveness